Pay in 4 interest-free payments of $6.48 Learn more
Ships within 48 hours Β· Estimated delivery Aug 26 - Aug 31
Willow is the only no-membership semaglutide provider that coordinates GLP-1 and HRT care together
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucose dependent insulinotropic polypeptide (GIP) are incretins which share similarity in terms of structure and function but exhibit diverse properties and functions
Your healthcare provider decides the best dose and length of treatment for you
A1C levels typically drop by 1.2%1.4% after six months on oral semaglutide, with 6977% of people reaching target levels below 7%
According to Renub Research, the global semaglutide market is projected to grow from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, expanding at a CAGR of 9.55% between 2025 and 2033
US$ 22.22
US$ 25.92
.webp)
US$ 22.33
US$ 25.46
US$ 27.61
US$ 27.32
US$ 25.73
US$ 26.64
